CLAIMS AS CURRENTLY PENDING IN THE APPLICATION

1. A compound of the following structural formula:



and pharmaceutically acceptable salts thereof wherein;

R_1 an R_2 are independently hydrogen, C_{1-6} alkyl, or R_1 and R_2 are joined to form pyrrolidine, piperidine, morpholine or imidazole;

X is OCH_3, SO_2R_3, SO_2CF_3 or CN;

R_3 is C_{1-6} alkyl or a C_{5-10} aromatic ring (optionally substituted with a halogen, hydroxyl or C_{1-6} alkyl optionally substituted with halogen or hydroxyl); and Y is hydrogen, Cl, Br, F, CN, $CONR_1R_2$, CF_3 OCH_3, $SO_2NR_1R_2$.

2. The compound of claim 1 wherein R_1 and R_2 are each propyl.

3. The compound of claim 1 wherein R_1 and R_2 are each methyl.

4. The compound of claim 1 wherein X is $-OCH_3$.

5. The compound of claim 1 wherein Y is hydrogen.

6. The compound of claim 1 which is

a) (R)-5-Methylamino-1-methoxy-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one;

b) R)-5-Dimethylamino-1-methoxy-5,6-dihydro 4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one;

c) R)-5-Propylamino-1-methoxy-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one;

d) R)-5-Dipropylamino-1-methoxy-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2 (1H)-one.

7. A method for treating anxiolylic disorders in animal or human hosts comprising the administration of a pharmaceutically effective amount of a compound of Formula I as set forth in claim 1.

8. The method of claim 7 wherein said compound is orally administered in an amount of from about 10 mg to about 1200 mg per day.

9. (R)-3-Methylamino-1,2,3,4-tetrahydroquinoline maleate.

10. (R)-3-Methy-1,2,3,4-tetrahydro-3-quinolinyl carbamic acid, phenylmethyl ester.

11. (R)-3-Methyl-1,2,3,4-tetrahydro-1-[methoxyamino)carbonyl]-3-quinolinyl]carbamic acid, phenylmethyl ester.

12. Methyl-(1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolinyl-5-yl)carbamic acid, phenylmethyl ester.

13. A compound of the following structural formula:



and pharmaceutically acceptable salts thereof wherein;

R_1 and R_2 are independently hydrogen, C_{1-6}alkyl, or carboxybenzyl or R_1 and R_2 are joined to form pyrrolidine, piperidine, morpholine or imidazole;

R_3 and R_4 are joined to form an X-substituted-imidazolin-2-one, -CONX-, when C_3 is either the R- or S-configuration;

X is OCH_3, SO_2R_5, SO_2CF_3, or CN;

R_5 is C_{1-6} alkyl or a C_{5-10} aromatic ring (optionally substituted with a halogen or hydroxyl); and

Y is hydrogen, Cl, Br, F, CN, $CONR_1R_2$, CF_3, OCH_3, $SO_2NR_1R_2$; and if

R_1 is hydrogen, R_2 is methyl, and C_3 is the R-configuration, R_3 and R_4 are hydrogen; and if

R_1 is methyl, R_2 is carboxybenzyl, C_3 is the R-configuration, and R_3 is hydrogen or $-CO(NH)OCH_3$, R_4 is hydrogen.